JYJiaqi Yu

Jiaqi Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jiaqi Yu has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Chongming Wu

    School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China

    2 shared publications
  • Hongju Xiang

    Department of Cardiovascular Medicine, Xiangxi Tujia and Miao Autonomous Prefecture People’s Hospital, The First Affiliated Hospital of Jishou University

    2 shared publications
  • Liping Du

    Medical College of Jishou University

    2 shared publications
  • Xiangyong Hu

    Department of Cardiovascular Medicine, Xiangxi Tujia and Miao Autonomous Prefecture People’s Hospital, The First Affiliated Hospital of Jishou University

    2 shared publications
  • Zhixiong Liao

    Department of Cardiovascular Medicine, Zhangjiajie People’s Hospital, Jishou University

    2 shared publications
  • Dong Liu

    State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China

    1 shared publication

Latest Publications

  • Open Access

    A biohybrid nanovesicle hijacks inflammatory chemotaxis to deliver colchicine for myocardial infarction therapy

    by Xiangyong Hu, Liping Du, Hongju Xiang, Yuyu Li, Zhixiong Liao, Jiaqi Yu

    Introduction: Myocardial infarction (MI) triggers an excessive inflammatory response that drives adverse cardiac remodeling. Although colchicine has shown clinical promise, its narrow therapeutic window and lack of target specificity limit its efficacy. To address these limitations, we developed a biohybrid nanovesicle (MM‐LP@COL) that encapsulates colchicine, aiming to leverage natural inflammatory tropism for site-specific drug delivery. Methods: MM‐LP@COL nanovesicles were fabricated by fusing macrophage membranes with liposomes. Physicochemical characterization was performed using DLS, TEM, and FRET analysis. Cytokine‐scavenging capacity was evaluated in vitro by ELISA. In a murine MI model, mice were treated with PBS, free colchicine, LP@COL, or MM‐LP@COL. Immune cell populations in blood, bone marrow, and spleen were analyzed by high‐dimensional flow cytometry (UMAP). Cardiac function and tissue remodeling were assessed by echocardiography and histology. Results: MM‐LP@COL formed uniform spherical nanovesicles (∼200 nm) and demonstrated potent, dose‐dependent neutralization of multiple pro‐inflammatory cytokines in vitro , along with reduced circulating cytokine levels in MI mice. High‐dimensional cytometric analysis revealed that treatment significantly reduced neutrophil infiltration across key immune organs, including blood, bone marrow, and spleen. These effects translated into improved left ventricular function, reduced myocardial inflammation, and attenuated cardiomyocyte hypertrophy. Discussion: This study demonstrates that the macrophage-inspired nanovesicle system constitutes a potent and targeted combinatorial therapy for post-infarction inflammation and repair.

  • Open Access

    Intestinal barrier damage is associated with fine particulate matter (PM2.5)-induced pathological aortic injury in mice

    by Xiangyong Hu, Ming Lei, Liping Du, Hongju Xiang, Jiaxin Hu, Jiaqi Yu, Zhixiong Liao, Yuyu Li

    Chronic exposure to air pollution is associated with an increased cardiovascular disease (CVD) risk, and inflammation induced by fine particulate matter (PM 2.5 ) exposure is a key driver in CVD development. However, the mechanism by which PM 2.5 causes cardiacovescular damage remains unclear. Here, Balb/c mice were intratracheally instilled with PM 2.5 suspension at doses of 2.0 mg/kg or 4.0 mg/kg body weight for 7 consecutive days to establish an aortic injury model. Pathological changes were assessed by hematoxylin and eosin (H&E), elastic Van Gieson, and Masson’s trichrome staining. Potential pathways were identified through GeneCards database analysis, R language, and Metascape pathway enrichment analysis. Immune cell profiles in the blood were analyzed by flow cytometry, and serum inflammatory cytokines were measured by enzyme-linked immunosorbent assay. Confocal microscopy was used to evaluate inflammatory cell infiltration in the aorta. Intestinal barrier integrity was assessed by transmission electron microscopy; H&E, and immunofluorescence staining; and western blotting. We found that high-dose PM 2.5 exposure led to inflammatory cell infiltration, disorganization of elastic fiber layers, and aortic tissue fibrosis. Pathway enrichment analyses indicated the involvement of pathways related to the regulation of inflammatory responses and responses to bacterial molecules. Increased inflammatory cells and pro-inflammatory cytokines were detected in the blood, accompanied by an increase in circulating lipopolysaccharide. PM 2.5 exposure disrupted the intestinal mucosal barrier, leading to reduced claudin-1 and occludin (tight junction protein) expression, which exacerbated systemic inflammation and induced aortic injury. In conclusion, PM 2.5 exposure caused pathological aortic damage and exacerbated systemic inflammation, potentially mediated by compromised intestinal barrier integrity.


  • Open Access

    Engineered Hybrid Nanovesicles Combining Macrophage Membranes and Artificial Lipids for Abdominal Aortic Aneurysm Therapy

    by Weiyao Chen, Jiling Zhao, Jiamin Xu, Heng Wu, Zhongnan Xia, Jie Liu, Shilong Sun, Yuhua Lei, Hongbo Chen, Jiaqi Yu, et al.

    Background and Aims: Abdominal aortic aneurysm (AAA) is a vascular condition with high mortality for which no pharmacological treatments have been approved. Targeting endothelial dysfunction as a primary disease initiator, the vascular endothelial cell (VEC)- protective compound Senkyunolide I (SEI) demonstrates therapeutic promise through robust antiapoptotic activity. Nevertheless, SEI’s clinical translation faces limitations due to systemic toxicity, necessitating development of safer therapeutic alternatives. Results: This study presents an engineered biomimetic nanoplatform (Lipo-MM nanoparticles) combining macrophage-derived membranes with synthetic lipid bilayers for targeted SEI delivery. The macrophage membrane component facilitates precise targeting of activated VECs, while optimized artificial membrane fluidity enhances nanoparticle stability. This dual-membrane configuration enables sustained SEI release with enhanced biodistribution, achieving superior cytoprotective effects. Notably, we established a novel fusion membrane delivery system (Lipo-MM/SEI) and validated its therapeutic efficacy in angiotensin II-challenged AAA murine models. The nanocarrier significantly attenuated AAA progression, reflected by decreased 40% of AAA incidence, 31.4% of maximum aortic diameter, reduced elastin degradation and prevented fatal rupture events. Furthermore, Lipo-MM/SEI administration substantially reduced hepatorenal toxicity associated with free SEI administration during chronic treatment. Conclusion: These results demonstrate that hybrid biomimetic systems integrating natural cellular components with engineered materials offer a strategic approach for vascular endothelial repair therapy while minimizing off-target effects. This membrane fusion technology establishes a prototype for developing next-generation targeted vascular therapeutics.


  • Open Access

    Asperlin Stimulates Energy Expenditure and Modulates Gut Microbiota in HFD-Fed Mice

    by Chongming Wu, Yue Zhou, Guihong Qi, Dong Liu, Xiaoxue Cao, Jiaqi Yu, Rong Zhang, Wenhan Lin, Peng Guo

    Asperlin is a marine-derived, natural product with antifungal, anti-inflammatory and anti-atherosclerotic activities. In the present study, we showed that asperlin effectively prevented the development of obesity in high-fat diet (HFD)-fed mice. Oral administration of asperlin for 12 weeks significantly suppressed HFD-induced body weight gain and fat deposition without inhibiting food intake. Hyperlipidemia and liver steatosis were also substantially ameliorated. A respiratory metabolism monitor showed that asperlin efficiently increased energy expenditure and enhanced thermogenic gene expression in adipose tissue. Accordingly, asperlin-treated mice showed higher body temperature and were more tolerant of cold stress. Meanwhile, asperlin also increased the diversity and shifted the structure of gut microbiota. Oral administration of asperlin markedly increased the relative abundance of Bacteroidetes, leading to a higher Bacteroidetes-to-Fimicutes ratio. The HFD-induced abnormalities at both phylum and genus levels were all remarkably recovered by asperlin. These results demonstrated that asperlin is effective in preventing HFD-induced obesity and modulating gut microbiota. Its anti-obesity properties may be attributed to its effect on promoting energy expenditure.